We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Viking Therapeutics, Inc. (VKTX) Stock Dips While Market Gains: Key Facts
Read MoreHide Full Article
Viking Therapeutics, Inc. (VKTX - Free Report) ended the recent trading session at $33.93, demonstrating a -2.5% change from the preceding day's closing price. This change lagged the S&P 500's daily gain of 0.44%. Elsewhere, the Dow gained 0.36%, while the tech-heavy Nasdaq added 0.54%.
Heading into today, shares of the company had gained 5.52% over the past month, outpacing the Medical sector's loss of 4.11% and the S&P 500's loss of 3.31%.
The investment community will be closely monitoring the performance of Viking Therapeutics, Inc. in its forthcoming earnings report. The company is predicted to post an EPS of -$1.01, indicating a 146.34% decline compared to the equivalent quarter last year.
For the full year, the Zacks Consensus Estimates are projecting earnings of -$4.15 per share and revenue of $0 million, which would represent changes of -30.09% and 0%, respectively, from the prior year.
Any recent changes to analyst estimates for Viking Therapeutics, Inc. should also be noted by investors. Such recent modifications usually signify the changing landscape of near-term business trends. As such, positive estimate revisions reflect analyst optimism about the business and profitability.
Based on our research, we believe these estimate revisions are directly related to near-term stock moves. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. Over the past month, there's been a 1.53% fall in the Zacks Consensus EPS estimate. Viking Therapeutics, Inc. currently has a Zacks Rank of #3 (Hold).
The Medical - Biomedical and Genetics industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 142, positioning it in the bottom 42% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow VKTX in the coming trading sessions, be sure to utilize Zacks.com.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Viking Therapeutics, Inc. (VKTX) Stock Dips While Market Gains: Key Facts
Viking Therapeutics, Inc. (VKTX - Free Report) ended the recent trading session at $33.93, demonstrating a -2.5% change from the preceding day's closing price. This change lagged the S&P 500's daily gain of 0.44%. Elsewhere, the Dow gained 0.36%, while the tech-heavy Nasdaq added 0.54%.
Heading into today, shares of the company had gained 5.52% over the past month, outpacing the Medical sector's loss of 4.11% and the S&P 500's loss of 3.31%.
The investment community will be closely monitoring the performance of Viking Therapeutics, Inc. in its forthcoming earnings report. The company is predicted to post an EPS of -$1.01, indicating a 146.34% decline compared to the equivalent quarter last year.
For the full year, the Zacks Consensus Estimates are projecting earnings of -$4.15 per share and revenue of $0 million, which would represent changes of -30.09% and 0%, respectively, from the prior year.
Any recent changes to analyst estimates for Viking Therapeutics, Inc. should also be noted by investors. Such recent modifications usually signify the changing landscape of near-term business trends. As such, positive estimate revisions reflect analyst optimism about the business and profitability.
Based on our research, we believe these estimate revisions are directly related to near-term stock moves. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. Over the past month, there's been a 1.53% fall in the Zacks Consensus EPS estimate. Viking Therapeutics, Inc. currently has a Zacks Rank of #3 (Hold).
The Medical - Biomedical and Genetics industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 142, positioning it in the bottom 42% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow VKTX in the coming trading sessions, be sure to utilize Zacks.com.